No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in rats
Journal Title: The AAPS Journal - Year 2000, Vol 2, Issue 3
Abstract
Fluvastatin, an amphiphilic anion, shows a nonlinear increase in effective intestinal permeability (Peff) with increasing lumenal concentrations in rats. The main objective of this study was to investigate whether or not this observation could be attributed to an efflux-mediated transport by the multidrug resistance-associated protein (MRP). In parallel, we investigated the possible involvement of the monocarboxylic acid transporter (MCT) in the rapid intestinal absorption of fluvastatin. Single-pass perfusions were performed in the ileum and colon of the rat, with and without the presence of well-established inhibitors/substrates for the MRP (probenecid) and the MCT (nicotinic acid). The results suggest that neither the MRP nor the MCT are involved to any significant extent in the absorption process of fluvastatin in the rat intestine. Thus, the previously reported concentration-dependent Peff of fluvastatin in these intestinal regions of the rat is probably not attributable to saturation of any efflux mediated by MRP.
Authors and Affiliations
Anders Lindahl, Sofia Frid, Anna-Lena Ungell, Hans Lennernäs
Keywords
Related Articles
- EP ID EP682103
- DOI 10.1208/ps020327
- Views 85
- Downloads 0
Estimation of capping incidence by indentation fracture tests
The purpose of this study was to predict the capping tendencies of pharmaceutical powders by creating indentation fracture on compacts. Three sets of binary mixtures containing different concentrations of each ingredient...
Ligand Binding Assay Critical Reagents and Their Stability: Recommendations and Best Practices from the Global Bioanalysis Consortium Harmonization Team
The L4 Global Harmonization Team on reagents and their stability focused on the management of critical reagents for pharmacokinetic, immunogenicity, and biomarker ligand binding assays. Regulatory guidance recognizes tha...
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was teste...
Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure
The online version of this article (doi:10.1208/s12248-013-9541-z) contains supplementary material, which is available to authorized users.
Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team
At the initiative of four regional professional organizations from Europe (European Bioanalysis Forum (EBF)) and North America (AAPS, Applied Pharmaceutical Analysis (APA) APA and Calibration & validation group (...